Changes to NRT licensing and use

摘要

In 2005,the Committee on Safety of Medicines(CSM)and the Medicines and Healthcare products Regulatory Agency(MHRA)reviewed indications for all forms of nicotine replacement therapy(NRT)and proposed new circumstances in which they can be used.This was to ensure that the benefits of therapy were maximised and that any risks associated with NRT were seen in the context of the far greater harm of continued smoking.